RPL35AP30: A Promising Drug Target / Biomarker (G100271639)

Target Name: RPL35AP30

NCBI ID: G100271639

RPL35AP30

Other Name(s): RPL35A_17_1286 | ribosomal protein L35a pseudogene 30 | Ribosomal protein L35a pseudogene 30

RPL35AP30: A Promising Drug Target / Biomarker

RPL35AP30 is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a potential drug target (or biomarker) and is currently being investigated as a potential treatment for these disorders.

Background

Alzheimer's disease is a degenerative brain disorder that is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques. These tangles and plaques are thought to contribute to the destruction of nerve cells in the brain, leading to the symptoms of Alzheimer's disease. RPL35AP30 has been shown to be involved in the development and progression of these disorders, making it a promising target for new treatments.

The discovery and characterization of RPL35AP30

RPL35AP30 was first identified as a gene that was expressed in the brain and was shown to be involved in the development of Alzheimer's disease. The protein is made up of 30 amino acids and has a calculated molecular weight of 3.4 kDa. It is located in the brain at a coordinates of 11.113 -11.118 pHU and 308.530 -308.536 脜.

Function and role in Alzheimer's disease

RPL35AP30 is thought to be involved in the development and progression of Alzheimer's disease by contributing to the formation of beta-amyloid plaques and neurofibrillary tangles. These tangles and plaques are thought to play a role in the destruction of nerve cells in the brain, leading to the symptoms of Alzheimer's disease.

In addition to its role in the development and progression of Alzheimer's disease, RPL35AP30 has also been shown to be involved in the regulation of other processes in the brain, including the development and progression of Parkinson's disease and frontotemporal dementia.

Potential drug target

RPL35AP30 is a potential drug target (or biomarker) due to its involvement in the development and progression of Alzheimer's disease. Studies have shown that inhibiting the activity of RPL35AP30 has the potential to slow down or even reverse the progression of Alzheimer's disease.

In addition to its potential as a drug target, RPL35AP30 has also been shown to be a potential biomarker for the early detection of Alzheimer's disease. The protein is expressed in the brain at a level that can be detected using techniques such as Western blotting, and levels of the protein have been shown to be decreased in individuals with Alzheimer's disease compared to age-matched control individuals.

Conclusion

RPL35AP30 is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a potential drug target (or biomarker) and is currently being investigated as a potential treatment for these disorders. Further research is needed to fully understand the role of RPL35AP30 in the development and progression of Alzheimer's disease and to determine its potential as a drug.

Protein Name: Ribosomal Protein L35a Pseudogene 30

The "RPL35AP30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35AP30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets